• 1
    Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
  • 2
    Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. 2009. National health statistics reports; no 13. National Center for Health Statistics: Hyattsville, MD: 2009.
  • 3
    Centers for Disease Control and Prevention and The Merck Company Foundation. The State of Aging and Health in America, 2007. Whitehouse Station, NJ: The Merck Company Foundation; 2007.
  • 4
    Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006;5:735-741.
  • 5
    Vanhanen M, Koivisto K, Moilanen L, et al. Association of metabolic syndrome with Alzheimer disease. Neurology 2006;67:843-847.
  • 6
    Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237-2242.
  • 7
    Fitzpatrick AL, Kuller LH, Lopez OL, et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009;66:336-342.
  • 8
    Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 2009;58:71-77.
  • 9
    Frisardi V, Solfrizzi V, Seripa D, et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 2010;9:399-417.
  • 10
    Rogers RL, Meyer JS, McClintic K, Mortel KF. Reducing hypertriglyceridemia in elderly patients with cerebrovascular disease stabilizes or improves cognition and cerebral perfusion. Angiology 1989;40:260-269.
  • 11
    Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings MI. Hypertension and longitudinal changes in cerebral blood flow: The SMART-MR study. Ann Neurol 2012;71:825-833.
  • 12
    Carlsson CM, Xu G, Wen Z, et al. Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's Disease: a pilot study. Curr Alzheimer Res 2011;Epub ahead of print.
  • 13
    Willeumier KC, Taylor DV, Amen DG. Elevated BMI is associated with decreased blood flow in the prefrontal cortex using SPECT imaging in healthy adults. Obesity (Silver Spring) 2011;19:1095-1097.
  • 14
    Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005;234:851-859.
  • 15
    Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 2005;18:245-249.
  • 16
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
  • 17
    Dowling NM, Hermann B, La Rue A, Sager MA. Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease. Neuropsychology 2010;24:742-756.
  • 18
    Spreen O, Strauss E. A Compendium of Neuropsychological Tests : Administration, Norms, and Commentary, 2nd edn. New York: Oxford University Press; 1998.
  • 19
    Wechsler D. WAIS-III: Wechsler Adult Intelligence Scale. Psychological Corporation, 1997.
  • 20
    Trenerry MR. Stroop Neuropsychological Screening Test Manual. Psychological Assessment Resources, 1989.
  • 21
    Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson: Neuropsychology Press, 1993.
  • 22
    Backman L, Jones S, Berger AK, Laukka EJ, Small BJ. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology 2005;19:520-531.
  • 23
    Ye FQ, Frank JA, Weinberger DR, McLaughlin AC. Noise reduction in 3D perfusion imaging by attenuating the static signal in arterial spin tagging (ASSIST). Magn Reson Med 2000;44:92-100.
  • 24
    Dai W, Garcia D, de Bazelaire C, Alsop DC. Continuous flow-driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields. Magn Reson Med 2008;60:1488-1497.
  • 25
    Garcia DM, Duhamel G, Alsop DC. Efficiency of inversion pulses for background suppressed arterial spin labeling. Magn Reson Med 2005;54:366-372.
  • 26
    Xu G, Rowley HA, Wu G, et al. Reliability and precision of pseudo-continuous arterial spin labeling perfusion MRI on 3.0 T and comparison with 15O-water PET in elderly subjects at risk for Alzheimer's disease. NMR Biomed 2010;23:286-293.
  • 27
    Tosun D, Mojabi P, Weiner MW, Schuff N. Joint analysis of structural and perfusion MRI for cognitive assessment and classification of Alzheimer's disease and normal aging. Neuroimage 2010;52:186-197.
  • 28
    Yakushev I, Hammers A, Fellgiebel A, et al. SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage 2009;44:43-50.
  • 29
    Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26:839-851.
  • 30
    Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A. A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010;50:1427-1437.
  • 31
    Schmidt P, Gaser C, Arsic M, et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage 2012;59:3774-3783.
  • 32
    O'brien R. A Caution regarding rules of thumb for variance inflation factors. Qual Quan 2007;41:673-690.
  • 33
    MacKinnon DP, Fairchild AJ, Fritz MS. Mediation analysis. Annu Rev Psychol 2007;58:593-614.
  • 34
    Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-2094.
  • 35
    Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-7717.
  • 36
    Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002;159:738-745.
  • 37
    Craft S, Zallen G, Baker LD. Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsychol 1992;14:253-267.
  • 38
    Yaffe K, Weston AL, Blackwell T, Krueger KA. The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol 2009;66:324-328.
  • 39
    Wolk DA, Dickerson BC. Fractionating verbal episodic memory in Alzheimer's disease. Neuroimage 2011;54:1530-1539.